Explore commercial and development batches produced under rigorous quality management, complete with full chromatographic batch-specific Certificates of Analysis.
Originally discovered through functional cDNA screening of brain sections from surviving Alzheimer's disease cohorts, Humanin (HN) is a 24-amino-acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene (MT-RNR2). Operating as a key endocrine regulator of cytoprotection, cell survival, and metabolic homeostasis, Humanin orchestrates defense against oxidative stress, apoptotic cascades, and inflammatory insults.
As an industry-leading CDMO and peptide API manufacturer operating out of Hangzhou, China, Hangzhou Thinheal Pharma-Tech Co., Ltd. offers customized research-to-commercial synthesis of native Humanin, stabilized analogs like HNG (S14G-Humanin), and conjugated delivery constructs. Backed by multi-ton chemical synthesis capacity and 20 years of technical management acumen, we resolve the substantial manufacturing barriers associated with this hydrophobic, aggregation-prone biomolecule.
Native Humanin consists of the specific canonical sequence:
From neurodegenerative prevention to metabolic intervention, Humanin addresses systemic senescence and ischemic disease via dual receptor and intracellular signaling.
Humanin acts as an endogenous antagonist of Bax-mediated mitochondrial apoptosis. It suppresses amyloid-β (Aβ1-42) oligomer neurotoxicity, preserves synaptic spine integrity, inhibits microglial over-activation, and prevents motor neuron apoptosis in Amyotrophic Lateral Sclerosis (ALS) experimental models.
Myocardial infarction and systemic atherosclerosis stem from vascular endothelial senescence and reperfusion oxidative injury. Humanin preserves endothelial nitric oxide synthase (eNOS) phosphorylation, limits infarct boundaries, and preserves left ventricular ejection fraction post-ischemia.
Acting in synergy with incretins (GLP-1/GIP), circulating Humanin enhances peripheral insulin sensitivity, prevents pancreatic β-cell apoptosis under gluco-lipotoxicity, and normalizes hepatic gluconeogenesis through hypothalamic STAT3 signaling pathways.
Retinal pigment epithelium (RPE) cellular exhaustion under relentless photo-oxidative stress underpins age-related macular degeneration (AMD). Exogenous Humanin concentrates in mitochondrial cristae, sustaining cell viability and shielding against endoplasmic reticulum (ER) stress.
Chronological aging correlates with an exponential decline in circulating endogenous mitochondrial peptides. Humanin supplementation is being pursued in geroscience pipelines to attenuate senescence-associated secretory phenotypes (SASP) and rebalance telomeric stability.
Thinheal synthesizes cosmetic-grade Humanin and lipid-conjugated variants (Palmitoyl-Humanin) targeting the mitochondrial rejuvenation of dermal fibroblasts, UV-induced cellular senescence reversal, and deep collagen matrix preservation.
Chemically assembling Humanin requires bespoke synthetic strategies to conquer extreme sequence hydrophobicity, steric hindrance, and side-chain oxidation.
The Core Chemical Barrier: The central domain of Humanin harbors four consecutive Leucine residues (Leu9-Leu10-Leu11-Leu12) flanked by Phenylalanine and Serine. This uninterrupted stretch of aliphatic residues generates potent intermolecular β-sheet intra-chain hydrogen bonding on polystyrene resins during standard Fmoc-SPPS, resulting in premature chain termination, incomplete couplings, and deletion impurities (ΔLeu isomers) that are notoriously difficult to separate via standard preparative HPLC.
| Synthesis Checkpoint | Conventional Industry Method | Thinheal Advanced CDMO Protocol | Quality & Yield Advantage |
|---|---|---|---|
| Solid Support Resin | Standard Wang or 2-Chlorotrityl Chloride Polystyrene resin (0.6–0.9 mmol/g) | Ultra-low loading PEG-PS or Tentagel-type Resins (0.18–0.25 mmol/g) | Minimizes sterical aggregation within resin beads; enables uniform sequence elongation. |
| Leu9-Leu12 Elongation | Standard Fmoc-Leu-OH with HBTU/DIPEA room temperature activation | Pseudoproline building blocks & high-efficiency Microwave-Assisted SPPS (60°C) | Breaks β-sheet secondary folding; eliminates truncated failure sequences to < 0.3%. |
| Cys8 Protection & Oxidation | Standard Trityl (Trt) side-chain protection | Orthogonal Acm or selective StBu protection under rigorous nitrogen purging | Completely eliminates spontaneous dimerization and Cys-β-elimination artifacts. |
| Cleavage Cocktail Matrix | 95% TFA, 2.5% TIS, 2.5% Water (Standard cleavage) | TFA / EDT / Thioanisole / Phenol / Water / TIS (82.5:5:5:5:2.5:2.5) at 4°C | Prevents methionine oxidation (Met1 sulfoxide formation) and back-alkylation. |
| Preparative Purification | Single-step C18 RP-HPLC gradient elution | Two-dimensional orthogonal RP-HPLC (TEAP buffer pH 2.5 followed by NH4OAc/MeCN) | Guarantees ≥ 98.5% main peak purity; resolves difficult diastereomers cleanly. |
Peptides manufactured via standard trifluoroacetic acid (TFA) cleavage retain TFA counter-ions, which exhibit potent cytotoxicity in cell cultures and clinical trials. Thinheal provides complete, validated counter-ion exchange to Acetate (AcO−) or Hydrochloride (HCl) salt forms. Lyophilization cycles are custom-mapped with programmed pre-freezing and secondary sublimation curves to deliver a stable, fluffy, easily reconstitutable cake.
We tailor custom Humanin derivatives for specific academic and biotech development milestones:
Every commercial batch produced at Thinheal is subjected to stringent multi-tiered release testing conforming to ICH Q6B guidelines for synthetic biotechnology products.
Assessed via high-resolution analytical RP-HPLC with dual-wavelength photodiode array detection (214 nm / 280 nm). We report all individual impurities ≥ 0.1%, quantifying deamidation, oxidation, and diastereomeric isomers.
High-resolution ESI-Q-TOF Mass Spectrometry confirms unambiguous molecular weight matching theoretical mass within ± 0.5 Da. Peptide sequence confirmation is executed via MS/MS fragmentation mapping.
Purity is distinct from net peptide content. Through Amino Acid Analysis (AAA) and elemental nitrogen testing, we quantify exact peptide versus counter-ion/water fractions to guarantee precision dosing.
Residual organic solvents (DMF, DCM, Acetonitrile, Piperidine, TFA) quantified via Headspace Gas Chromatography (GC-HS) strictly conforming to ICH Q3C Class 2 and Class 3 safety thresholds.
Rigorous chromogenic Limulus Amebocyte Lysate (LAL) testing guaranteeing bacterial endotoxin levels < 10 EU/mg (or < 5 EU/mg upon customer specification) for preclinical in vivo applications.
Karl Fischer coulometric titration determines residual water content (≤ 5.0%), while ICP-MS detects elemental trace impurities (Lead, Arsenic, Cadmium, Mercury) to parts-per-billion sensitivity.
Ensuring end-to-end supply chain continuity across North America, the European Union, the CIS region, the Middle East, and the Asia-Pacific territory.
Entering translational clinical trials demands comprehensive chemistry, manufacturing, and controls (CMC) documentation. Thinheal provides regulatory support documentation formatted to global agency specifications:
Thinheal operates specialized time-zone-aligned technical sales and project management desks to ensure effortless communication:
Charting the industrial transition toward greener chemical synthesis, continuous flow technology, and targeted non-invasive delivery modalities.
Phasing out hazardous dipolar aprotic solvents (DMF, NMP) in favor of non-toxic, eco-responsible alternatives such as 2-MeTHF, CPME, and bio-derived γ-valerolactone. Achieving a 60% reduction in Process Mass Intensity (PMI) across multi-kilogram Humanin campaigns.
Deploying continuous packed-bed flow reactors to synthesize Humanin and HNG analogs in real time. Microfluidic heating achieves near-instantaneous coupling of sterically hindered Leucine residues within seconds, compressing synthesis turnaround times from days to hours.
Integration of Humanin peptides into lipid nanoparticle (LNP) carriers, transferrin-receptor conjugated shuttles, and exosome biomimetic systems. Enabling non-invasive intranasal and systemic delivery directly crossing the blood-brain barrier for Alzheimer's and Parkinson's intervention.
Essential scientific and commercial answers designed for biopharma procurement managers and research directors.
Explore our broader therapeutic peptide offerings spanning GLP-1 analogues, incretin co-agonists, reproductive hormones, and specialty cardiovascular APIs.
Whether you require exploratory milligram quantities of stabilized HNG analogs or multi-ton commercial contract manufacturing, Hangzhou Thinheal Pharma-Tech Co., Ltd. delivers the synthesis expertise, analytical validation, and regulatory dossiers your pipeline demands.
Thin